×
About 374 results

ALLMedicine™ Struma Ovarii Center

Research & Reviews  187 results

Clinical characteristics and survival outcomes of malignant struma ovarii confined to t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033663
BMC Cancer; Li S, Yang T et. al.

Apr 10th, 2021 - Malignant struma ovarii (MSO) is a unique type of ovarian malignancy that data on the survival outcome is limited and management strategy remains controversial due to its extreme rarity. To investigate the clinical characteristics and treatment op...

Malignant struma ovarii: surgical, histopathological and survival outcomes for thyroid-...
https://doi.org/10.1007/s00404-021-05969-0 10.1186/s13044-017-0038-1 10.5858/134.5.786 10.1089/thy.2014.0328 10.1210/jc.2013-1782 10.1097/PAS.0b013e31802f5404 10.1159/000108654 10.1097/00000478-199312000-00002 10.7863/jum.2000.19.12.857 10.1089/thy.2006.16.791 10.1007/BF03347575 10.1089/thy.2009.0458 10.1007/BF03401528 10.1089/thy.2010.0022 10.1089/thy.2011.0162
Archives of Gynecology and Obstetrics; Addley S, Mihai R et. al.

Jan 29th, 2021 - Struma ovarii is rare, accounting for 0.3-1% of ovarian tumours. Malignant transformation may occur, most often into papillary thyroid carcinoma. There is a paucity of data pertaining to malignant struma ovarii. This paper shares a decade of exper...

Metabolic Response by 18F-FDG PET/CT in Metastatic Malignant Struma Ovarii Treated With...
https://doi.org/10.1097/RLU.0000000000003374
Clinical Nuclear Medicine; Seban RD, Bozec L et. al.

Nov 12th, 2020 - Malignant struma ovarii (MSO) is a rare malignant ovarian tumor, histologically identical to differentiated thyroid cancers. Given the rarity of this disease, there are no treatment guidelines, and the place of imaging for response assessment rema...

Methylation profiles of imprinted genes are distinct between mature ovarian teratoma, c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817522
Modern Pathology : an Official Journal of the United Stat... Kato N, Kamataki A et. al.

Sep 2nd, 2020 - Mature ovarian teratoma is considered to be a parthenogenetic tumor that arises from a single oocyte/ovum. Conversely, complete hydatidiform mole (CHM) is androgenetic in origin: classic CHM arises from a single or two sperm. Since mature ovarian ...

Thyroid tissue outside the thyroid gland: Differential diagnosis and associated diagnos...
https://doi.org/10.1016/j.anndiagpath.2020.151584
Annals of Diagnostic Pathology; Barbieri A, Prasad ML et. al.

Sep 1st, 2020 - The presence of thyroid tissue outside of the thyroid gland may occur in various clinical settings and anatomic locations and includes both benign and malignant differential diagnoses. Some of these entities include thyroglossal duct cyst, lingual...

see more →

Clinicaltrials.gov  187 results

Clinical characteristics and survival outcomes of malignant struma ovarii confined to t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033663
BMC Cancer; Li S, Yang T et. al.

Apr 10th, 2021 - Malignant struma ovarii (MSO) is a unique type of ovarian malignancy that data on the survival outcome is limited and management strategy remains controversial due to its extreme rarity. To investigate the clinical characteristics and treatment op...

Malignant struma ovarii: surgical, histopathological and survival outcomes for thyroid-...
https://doi.org/10.1007/s00404-021-05969-0 10.1186/s13044-017-0038-1 10.5858/134.5.786 10.1089/thy.2014.0328 10.1210/jc.2013-1782 10.1097/PAS.0b013e31802f5404 10.1159/000108654 10.1097/00000478-199312000-00002 10.7863/jum.2000.19.12.857 10.1089/thy.2006.16.791 10.1007/BF03347575 10.1089/thy.2009.0458 10.1007/BF03401528 10.1089/thy.2010.0022 10.1089/thy.2011.0162
Archives of Gynecology and Obstetrics; Addley S, Mihai R et. al.

Jan 29th, 2021 - Struma ovarii is rare, accounting for 0.3-1% of ovarian tumours. Malignant transformation may occur, most often into papillary thyroid carcinoma. There is a paucity of data pertaining to malignant struma ovarii. This paper shares a decade of exper...

Metabolic Response by 18F-FDG PET/CT in Metastatic Malignant Struma Ovarii Treated With...
https://doi.org/10.1097/RLU.0000000000003374
Clinical Nuclear Medicine; Seban RD, Bozec L et. al.

Nov 12th, 2020 - Malignant struma ovarii (MSO) is a rare malignant ovarian tumor, histologically identical to differentiated thyroid cancers. Given the rarity of this disease, there are no treatment guidelines, and the place of imaging for response assessment rema...

Methylation profiles of imprinted genes are distinct between mature ovarian teratoma, c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817522
Modern Pathology : an Official Journal of the United Stat... Kato N, Kamataki A et. al.

Sep 2nd, 2020 - Mature ovarian teratoma is considered to be a parthenogenetic tumor that arises from a single oocyte/ovum. Conversely, complete hydatidiform mole (CHM) is androgenetic in origin: classic CHM arises from a single or two sperm. Since mature ovarian ...

Thyroid tissue outside the thyroid gland: Differential diagnosis and associated diagnos...
https://doi.org/10.1016/j.anndiagpath.2020.151584
Annals of Diagnostic Pathology; Barbieri A, Prasad ML et. al.

Sep 1st, 2020 - The presence of thyroid tissue outside of the thyroid gland may occur in various clinical settings and anatomic locations and includes both benign and malignant differential diagnoses. Some of these entities include thyroglossal duct cyst, lingual...

see more →